位置:首页 > 蛋白库 > AK_CORFL
AK_CORFL
ID   AK_CORFL                Reviewed;         421 AA.
AC   P41398;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   03-AUG-2022, entry version 109.
DE   RecName: Full=Aspartokinase;
DE            EC=2.7.2.4;
DE   AltName: Full=Aspartate kinase;
GN   Name=lysC; Synonyms=ask;
OS   Corynebacterium flavescens.
OC   Bacteria; Actinobacteria; Corynebacteriales; Corynebacteriaceae;
OC   Corynebacterium.
OX   NCBI_TaxID=28028;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], MUTAGENESIS OF ASP-345, AND ACTIVITY
RP   REGULATION.
RC   STRAIN=N13;
RX   PubMed=8100567; DOI=10.1128/jb.175.13.4096-4103.1993;
RA   Follettie M.T., Peoples O.P., Agoropoulou C., Sinskey A.J.;
RT   "Gene structure and expression of the Corynebacterium flavum N13 ask-asd
RT   operon.";
RL   J. Bacteriol. 175:4096-4103(1993).
CC   -!- FUNCTION: Catalyzes the phosphorylation of the beta-carboxyl group of
CC       aspartic acid with ATP to yield 4-phospho-L-aspartate, which is
CC       involved in the branched biosynthetic pathway leading to the
CC       biosynthesis of amino acids lysine, threonine, isoleucine and
CC       methionine. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-aspartate = 4-phospho-L-aspartate + ADP;
CC         Xref=Rhea:RHEA:23776, ChEBI:CHEBI:29991, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:57535, ChEBI:CHEBI:456216; EC=2.7.2.4;
CC   -!- ACTIVITY REGULATION: Low feedback inhibition by lysine and threonine.
CC       The decreased sensitivity of C.flavum, as compared to C.glutamicum, is
CC       probably due to the Asp-345-Gly sequence difference.
CC       {ECO:0000269|PubMed:8100567}.
CC   -!- PATHWAY: Amino-acid biosynthesis; L-lysine biosynthesis via DAP
CC       pathway; (S)-tetrahydrodipicolinate from L-aspartate: step 1/4.
CC   -!- PATHWAY: Amino-acid biosynthesis; L-methionine biosynthesis via de novo
CC       pathway; L-homoserine from L-aspartate: step 1/3.
CC   -!- PATHWAY: Amino-acid biosynthesis; L-threonine biosynthesis; L-threonine
CC       from L-aspartate: step 1/5.
CC   -!- SUBUNIT: Tetramer consisting of 2 isoforms Alpha (catalytic and
CC       regulation) and of a homodimer of 2 isoforms Beta (regulation).
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=Alpha; Synonyms=Aspartokinase subunit alpha;
CC         IsoId=P41398-1; Sequence=Displayed;
CC       Name=Beta; Synonyms=Aspartokinase subunit beta;
CC         IsoId=P41398-2; Sequence=VSP_018657, VSP_018658;
CC   -!- SIMILARITY: Belongs to the aspartokinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L16848; AAA23293.1; -; Genomic_DNA.
DR   AlphaFoldDB; P41398; -.
DR   SMR; P41398; -.
DR   UniPathway; UPA00034; UER00015.
DR   UniPathway; UPA00050; UER00461.
DR   UniPathway; UPA00051; UER00462.
DR   GO; GO:0004072; F:aspartate kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019877; P:diaminopimelate biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0009089; P:lysine biosynthetic process via diaminopimelate; IEA:UniProtKB-UniPathway.
DR   GO; GO:0016310; P:phosphorylation; IEA:UniProtKB-KW.
DR   GO; GO:0009088; P:threonine biosynthetic process; IEA:UniProtKB-UniPathway.
DR   CDD; cd04261; AAK_AKii-LysC-BS; 1.
DR   Gene3D; 3.40.1160.10; -; 1.
DR   InterPro; IPR036393; AceGlu_kinase-like_sf.
DR   InterPro; IPR045865; ACT-like_dom_sf.
DR   InterPro; IPR002912; ACT_dom.
DR   InterPro; IPR041740; AKii-LysC-BS.
DR   InterPro; IPR001048; Asp/Glu/Uridylate_kinase.
DR   InterPro; IPR005260; Asp_kin_monofn.
DR   InterPro; IPR001341; Asp_kinase.
DR   InterPro; IPR018042; Aspartate_kinase_CS.
DR   InterPro; IPR027795; CASTOR_ACT_dom.
DR   Pfam; PF00696; AA_kinase; 1.
DR   Pfam; PF01842; ACT; 1.
DR   Pfam; PF13840; ACT_7; 1.
DR   PIRSF; PIRSF000726; Asp_kin; 1.
DR   SUPFAM; SSF53633; SSF53633; 1.
DR   SUPFAM; SSF55021; SSF55021; 2.
DR   TIGRFAMs; TIGR00656; asp_kin_monofn; 1.
DR   TIGRFAMs; TIGR00657; asp_kinases; 1.
DR   PROSITE; PS51671; ACT; 2.
DR   PROSITE; PS00324; ASPARTOKINASE; 1.
PE   1: Evidence at protein level;
KW   Alternative initiation; Amino-acid biosynthesis; ATP-binding;
KW   Diaminopimelate biosynthesis; Kinase; Lysine biosynthesis;
KW   Nucleotide-binding; Repeat; Transferase.
FT   CHAIN           1..421
FT                   /note="Aspartokinase"
FT                   /id="PRO_0000002377"
FT   DOMAIN          267..343
FT                   /note="ACT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01007"
FT   DOMAIN          349..421
FT                   /note="ACT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01007"
FT   BINDING         7..10
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         25..30
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         41
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         45..49
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         74
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         125..126
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         151..154
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         154
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         174..175
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         180..185
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         210
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   BINDING         274..279
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         274
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         292..294
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         298
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         360..361
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         374..375
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         381..382
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   SITE            7
FT                   /note="Contribution to the catalysis"
FT                   /evidence="ECO:0000250"
FT   SITE            74
FT                   /note="Contribution to the catalysis"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..249
FT                   /note="Missing (in isoform Beta)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_018657"
FT   VAR_SEQ         250
FT                   /note="V -> M (in isoform Beta)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_018658"
FT   MUTAGEN         345
FT                   /note="D->G: Decreased sensitivity of AK activity to
FT                   concerted feedback inhibition by lysine and threonine."
FT                   /evidence="ECO:0000269|PubMed:8100567"
SQ   SEQUENCE   421 AA;  44797 MW;  4B37B0B6597F665E CRC64;
     MALVVQKYGG SSLESAERIR NVAERIVATK KAGNDVVVVC SAMGDTTDEL LELAAAVNPV
     PPAREMDMLL TAGERISNAL VAMAIESLGA EAQSFTGSQA GVLTTERHGN ARIVDVTPGR
     VREALDEGKI CIVAGFQGVN KETRDVTTLG RGGSDTTAVA LAAALNADVC EIYSDVDGVY
     TADPRIVPNA QKLEKLSFEE MLELAAVGSK ILVLRSVEYA RAFNVPLRVR SSYSNDPGTL
     IAGSMEDIPV EEAVLTGVAT DKSEAKVTVL GISDKPGEAA KVFRALADAE INIDMVLQNV
     SSVEDGTTDI TFTCPRADGR RAMEILKKLQ VQGNWTNVLY DDQVDKVSLV GAGMKSHPGV
     TAEFMEALRD VNVNIELIST SEIRISVLIR EDDLDAAARA LHEQFQLGGE DEAVVYAGTG
     R
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024